Ambispective registry of adults with lung cancer at Policlinico San Matteo
Ambispective Registry of Patients Affected by Lung Cancer
This registry will collect medical data from adults with lung cancer treated at Policlinico San Matteo from 2019 to 2035 to see how treatments, side effects, and survival compare in real-world care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Pavia) |
| Trial ID | NCT07274163 on ClinicalTrials.gov |
What this trial studies
This ambispective registry will gather retrospective data back to 2019 and prospective data through 2035 on adults treated for lung cancer at the SC Oncologia 1 Unit of Fondazione IRCCS Policlinico San Matteo. It will record diagnoses, tumor characteristics, treatments (including targeted therapies and immunotherapies), responses, adverse events, progression, and overall survival using the REDCap platform. Eligible patients are adults (≥18) who were treated at the center and who provide informed consent or have previously authorized use of their data. Data will be used to describe real-world treatment patterns and outcomes and to support future care and research while maintaining secure, de-identified records.
Who should consider this trial
Good fit: Adults (age ≥18) diagnosed with lung cancer and treated at the SC Oncologia 1 Unit of Fondazione IRCCS Policlinico San Matteo who can give informed consent or who previously agreed to data use are ideal candidates.
Not a fit: Patients who cannot understand or sign informed consent or who were not treated at the center are not eligible and therefore unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the registry could improve understanding of which treatments work best in routine practice and help personalize care for future lung cancer patients.
How similar studies have performed: Similar institutional and national lung cancer registries have successfully described real-world outcomes and informed treatment guidelines, so this approach is established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients ≥ 18 years diagnosed with and/or treated for lung cancer at the department of SC Oncologia 1 Unit of the Fondazione IRCCS Policlinico San Matteo; * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document; * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease. Exclusion Criteria: * Patients who are unable to understand informed consent document.
Where this trial is running
Pavia
- Fondazione IRCCS Policlinico San Matteo — Pavia, Italy (Recruiting)
Study contacts
- Study coordinator: Francesco Agustoni
- Email: f.agustoni@smatteo.pv.it
- Phone: 0382501433
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.